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Abstract
Background: Previously designed intra-thoracic paraaortic counterpulsation device has limited stroke volume and
may depress the lung to cause complications. The purpose of this study was to evaluate the hemodynamic effects
of an extra-thoracic paraaortic counterpulsation device (ETPACD) in comparison to intraaortic balloon pump (IABP)
in an animal model with acute heart failure.
Methods: The acute heart failure model was successfully induced by snaring branch of anterior descending
coronary artery in sheep (weighting, 38-50 kg, n = 8). The ETPACD is a single port, 65-ml stroke volume blood
chamber designed to be connected to descending aorta through a valveless graft and placed extra-thorax. In
comparison, a standard clinical 40-ml IABP was placed in the descending aorta. The hemodynamic indices of both
devices were recorded during counterpulsation assistance. Two of the sheep were allowed to survive for 1 week to
examine the prolonged effect.
Results: Both ETPACD and IABP increased cardiac output with higher effect of ETPACD (13.52 % vs. 8.19 % in IABP,
P < 0.05) and on mean diastolic aortic pressure (26.73 % vs. 12.58 % in IABP, P < 0.01). Both ETPACD and IABP also
produced a greater reduction in left ventricular end-diastolic pressure (26.77 % vs. 23.08 %, P > 0.05). The ETPACD
increased left carotid artery flow more significantly the IABP (18.00 % vs. 9.19 % , P < 0.05). In two of the sheep
allowed to survive for 1 week, the device worked well with no complications and there was no thrombus formation
in the chamber of ETPACD.
Conclusions: This study demonstrated that both ETPACD and IABP provided benefit of circulatory support in acute
heart failure with better effect on hemodynamic parameters provided by ETPACD. Therefore, ETPACD with
theoretical larger stroke volume may become a promising counterpulsation device for treatment of heart failure.
Keywords: Heart failure, Ventricular assist device
Background
The incidence of congestive heart failure (CHF) is in-
creasing worldwide, with more than one million new
cases diagnosed annually. Current treatment options for
CHF include optimal medical management therapy,
mechanical ventricular assist, and heart transplantation.
Over the past four decades, the intra-aortic balloon
pump (IABP) is the most widely used short-term cardiac
assist device with over 160,000 balloons implanted each
year worldwide with up to 65 % successful clinical out-
comes [1–3]. Despite notable advantages, including wide
availability, percutaneous insertion, acceptable cost, and
proven efficacy, the long-term use of the IABP to
support patients with end-stage heart failure were ser-
iously limited by vascular complications [4, 5], complete
immobilization of the patient, a high incidence of poor
results in presence of particularly severe cardiogenic
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shock and very low aortic pressures. The paraaortic
counterpulsation device (PACD) has been proposed as
an alternative for mechanical support of severe heart
failure in patients [6]. It is a pneumatically driven,
double or half-round, polyurethane chamber with a
valveless orifice connected to the ascending or descend-
ing aorta through a Dacron vascular graft. This device,
with counterpulsation volumes from 20 to 100 ml, was
found superior to the IABP and effective even at very
low levels of aortic pressure in short-term experiments
[7–12]. In addition, the long-term efficacy and high
biocompatibility of the PACD observed in chronic exper-
iments [12] have been verified clinically [8]. However,
main obstacles remain in the widespread clinical use of
the PACD such as the complications of implantation
and difficulties in closure of patient’s thoracic cavity.
The present study was designed to compare the
hemodynamic efficacy of a 65-ml stroke volume
ETPACD to the 40-ml IABP in an acute heart failure
model and to explore feasible surgical procedures in
placing extracorporeal (extra-thoracic) ETPACD in
order to facilitate the closure of the chest and to avoid
the complications in placing the device in an intra-
thoracic location.
Materials and methods
A new extra-thoracic paraaortic counterpulsation device
(ETPACD) (Fig. 1) (made in Dong Guan Ke Wei Medical
Apparatus Co. Ltd., Title: A Paraaortic Counterpulsation
Device . Patent Number: ZL 200920095633.X), the core
component of the device is a 65-ml stroke volume polyur-
ethane blood chamber, connected to the aorta by a
valveless graft (Fig. 2). A drive line runs from the other
chamber to an pneumatic driver. During systole, the drive
console evacuates (helium) gas from the chamber thus re-
moving blood from the aorta reducing cardiac work and
afterload. During diastole, the console ejects blood from
the blood chamber of the device into the aorta to provide
augmentation of diastolic pressure and to improve coron-
ary perfusion. The blood chamber has been specifically
developed for continuous washing and nominal shear
stress. The shape of the ETPACD is designed to double
half-ball and wash continuously by creating a constant but
shifting circular vortex of blood to minimize risk of
thrombosis. The graft of the device connects seamlessly to
the chamber without an inlet or outlet valve and sup-
ported with reinforcement rings. The distance between
the chamber and descending aorta is minimized to reduce
the risk of graft kinking and to improve efficiency.
Animal preparations
The acute heart failure model was successfully established
by snaring branch of descending coronary artery in eight
healthy adult sheep (weighting 38-50 kg). All animals were
offered standard humane care in compliance with the
“Guide for the Care and Use of Laboratory Animals,” pub-
lished by the National Institutes of Health (NIH publication
85–23, revised 1983). Ethical consent was approved by
Ethics Committee of Laboratory Animals of TEDA Inter-
national Cardiovascular Hospital. Food and water were
withheld for 48, 24 h before the operation. The animals
were premedicated with ketamine hydrochloride, 3 mg/kg
(Gutian Pharmaceutical CO., Ltd, Fujian Province, China)
midazolam, 0.1 mg/kg (Enhua Pharmaceutical CO., Ltd,
Jiangsu Province, China), and anesthesia was induced with
Propofol, 0.5 ml/kg i.v. (Libang Pharmaceutical CO., Ltd,
Xian, China) administered as an slow i.v. injection. The tra-
chea was intubated with a 7.5-mm cuffed endotracheal
tube, followed by suxamethonium chloride, 1.0 mg/kg i.v.
(Xudong Haipu Pharmaceutical CO., Ltd, Shanghai, China)
for analgesia and neuromuscular blockade with ethrane
(1 %–3 %) and fentanyl, 0.03 mg/kg i.v., respectively. Venti-
lation was controlled by intermittent positive pressure to
maintain a PaO2 above 100 mmHg and the end-tidal CO2
between 30 and 40 mmHg. Anesthesia and analgesia were
maintained by continuous intravenous infusions of Pro-
pofol 0.15 ml/kg/h and fentanyl 0.03 mg/kg/h. Neuro-
muscular blockade was maintained by a continuous
intravenous infusion of suxamethonium chloride.
Surgical procedures
The right external jugular vein was surgically exposed
and cannulated with a 7.5 F Swan-Ganz catheter
(Edwards Lifesciences LLC, USA ) to monitor the right
atrial, right ventricle, and pulmonary arterial pressure, and
to administer fluids. The left lateral thoracotomy was
Fig. 1 Photograph of an extra-thorax paraaortic counterpulsation
device (ETPACD). The ETPACD sac fills with 120-ml (a 65-ml
stroke) blood volume (1) during ventricular systole and empties
during ventricular diastole through a single valveless cannula (2).
The diaphragm is pneumatically driven by the console through a
gas line (3) and the gas outlet (4)
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performed through the 4th intercostal space. Heparin
1 mg/kg was given by i.v. and ACT was maintained above
200 s. The descending aorta was partially clamped by a
Satinski clamp and the Dacron vascular graft of ETPACD
with the orifice of 12 mm in diameter was anastomosed
end-to-side to the descending aorta. The ETPACD used in
this study was the blood chamber, separated from the gas
chamber by a movable polyurethane membrane (Fig. 1). It
had a pumping 65-ml stroke volume when fully inflated.
The gas conduit was directly connected to the driving line
of the console. A 4 F multipurpose catheter was inserted
through the left ventricular apex to record the left ven-
tricular pressure. The experimental preparation was com-
pleted with the insertion of a standard 40-ml intraaortic
balloon into the descending aorta via the surgically ex-
posed left femoral artery . Baseline hemodynamic mea-
surements were made before acute heart failure.
Left ventricular failure model
After the pericardial sac was opened, left ventricular fail-
ure was induced by ligation of the left descending coron-
ary artery and/or circumflex coronary arterial branches,
starting from the peripheral segments of the left anterior
descending coronary artery and lidocaine (2 mg/kg/h)
was administered intravenously to prevent ventricular
arrhythmias. The heart rate (HR), systolic aortic pressure
(SAP), the mean aortic diastolic pressure (MADP), the
central venous pressure (CVP), and the cardiac output
(CO) were continuously monitored. After the acute
heart failure model was successfully established, baseline
hemodynamic measurements were made without mech-
anical support. The chest incision was then closed by
layers around the vascular graft that was fixed by a short
plastic tube to avoid kinking of the graft.
After the surgical procedure, the mechanical support
was randomly initiated either by the IABP or by the
ETPACD in each experiment. Both devices were driven
by the same console (Datascope 98, Datascope Corp.,
Montvale, NJ, USA) and synchronization with the elec-
trocardiogram (ECG) was used to provide air chamber
inflation during diastole. Hemodynamic indices and the
left carotid artery flow (LCAF) were recorded or calcu-
lated during 1) baseline (device off ) and 2) 1:2 support
for the 65-ml OTPACD or 40-ml IABP in the same
animal. Baseline measurements were repeated between
test conditions to ensure that CHF baseline values were
maintained at a comparably steady state. In each experi-
ment, the baselines and support mode for each device
were maintained for 15 min to ensure a steady-state was
reached. Data were collected for 60 s at the end of each
steady-state test condition. The test order of devices
(IABP and ETPACD) and support modes (1:2) were
randomized to eliminate experimental order bias.
Free hemoglobin and necropsy
Venous blood samples were drawn to measure total
hemoglobin and plasma free hemoglobin for each ex-
perimental test condition and device trial. At the com-
pletion of the experiment, the blood chamber and graft
of ETPACD were removed and visually inspected for
gross evidence of thrombus, fractures, and other defects.
Peripheral organs were removed and microscopical slides
were prepared to examine thrombus related infarcts.
Postoperative survival
In two of the sheep that had ETPACD, the ETPACD was
continued to postoperative period with the continuation
of the ETPACD support for 1 week (see Fig. 5a) with no
major complications. The anti-coagulant therapy was
continued by using heparin (1.0-2.0 mg/h) for 48 h to
maintain ACT at 150–180 s and followed by oral war-
farin (4.5-7.5 mg/day, dissolved in drinking water) after-
wards to maintain INR at 1.5-2.0.
Fig. 2 Photograph of experimental setup for the 65-ml extra-thoracic paraaortic counterpulsation device (ETPACD) in the acute heart failure sheep
model. a. The vascular graft is anastomosed to the descending aorta and the device is left extracorporeal location with the thorax open; b. View
of ETPACD after closure of the chest
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Statistical analysis
BIOPAC’s AcqKnowledge 3.9 was used for post-acquixsi-
tion processing of hemodynamic data. The hemodynamic
data acquired during the ETPACD- or IABP-assisted con-
dition were compared with data acquired before the
device-assistance. Data are presented as mean ± standard
deviation. When the comparisons involved only two
groups, the Student’s t-test for paired observations was
used. The multiple comparisons among three groups were
performed by One-Way ANOVA test with SPSS 13.0. A p
value < 0.05 was considered statistically significant.
Results
The acute heart failure model was successfully estab-
lished in eight animals. The hemodynamic parameters
before and after acute heart failure are shown in Table 1.
Complete hemodynamic data before and during mech-
anical support by the IABP or ETPACD are shown in
Table 2 and Fig. 3). Both IABP and ETPACD improved
hemodynamic indices. However, the improvement by
ETPACD was significantly greater than that by IABP.
The left carotid artery flow was improved by 9.2 % in
IABP (P <0.01) and 18.0 % in ETPACD (P <0.05) with
more improvement by ETPACD, compared to IABP, P
<0.05 (Fig. 4).
The plasma free hemoglobin levels remained 14-
37 mg/L for the whole experiments. At the completion
of the experiment, the blood chamber and graft of
ETPACD were removed and there was neither gross evi-
dence of thrombus, fractures, and other defects nor
thrombus related infarcts.
In two of the sheep that had the ETPACD continu-
ously used postoperatively for 1 week (Fig. 5), the device
worked well with no complications. One week later, the
sheep was sacrificed and the ETPACD was examined
for possible thrombus formation. Neither of these sheep
had thrombus formation in the chamber of ETPACD
(Fig. 5b).
Discussion
In the present study, we compared the efficiency of
ETPACD with 65 ml stroke volume to that of IABP and
we have found that 1) in treatment of acute heart failure,
this device has higher efficiency than IABP also both
work well and 2). The extra-thoracic location of the de-
vice is surgically feasible at least in the acute condition.
As mentioned above, heart failure is a major public
health problem in the world, associated with high mor-
bidity and mortality, estimated to impact over 20 million
people worldwide. Intra-aortic balloon pump (IABP) is a
commonly used form of circulatory support, often for
cardiogenic shock or severe left ventricular dysfunction
following acute myocardial infarction or cardiotomy
[13, 3] with acceptable survival (65 %) [2]. IABP worked
to reduce afterload, increased diastolic aortic pressure,
and increased coronary perfusion, in addition to pro-
moting a slight increase in cardiac output. However, ap-
plication of IABP is associated with a wide variety of
complications, especially long-term assisting, the most
common being bleeding, systemic embolization, limb
ischemia, amputation and infection. IABP may also be
associated with mechanical failure, such as balloon rup-
ture, inadequate inflation, or inadequate diastolic aug-
mentation. Particularly, IABP-related vascular
complications have been reported in multiple studies,
with an incidence of 8.7 % to 33 % [14–16].
On the other hand, although PACD was suggested to
be a useful method to treat heart failure a few decades
ago, its clinical use has been very limited and only few
clinical reports on the use of PACD [8]. Reasons ac-
counting for its limited use include depression of the
thoracic organs, especially the lung that results in atelec-
tasis and intrapulmonary infection leading to pulmonary
dysfunction. Another problem is when the device is
placed intra-thorax, the counterpulsation sac may be de-
pressed resulting reduced function. In addition, one of the
benefits of PACD is that its stroke volume is larger than
IABP. The current experiments used a stroke volume of
65 cc with possibility to increase it to 80 cc or even
more. This is obviously beneficial to the superior
hemodynamic effect over IABP. However, with the
quite large size of the device, when it is placed in the
chest, it not only depresses the lung but also, may cause
difficulties to close the chest.
Based on these considerations, we have designed a
new extra-thorax paraaortic counpepulsation device. The
present study has demonstrated the efficiency of this
device. Indeed, we have shown that the hemodynamic
improvement of this device is greater than IABP. By using
ETPACD, the possible vascular complications of implant-
ation of IABP is avoided. In addition, leaving the device
extra-thorax, the ETPACD does not depress the lung and
the closure of the chest become no problem. This gives a
possibility in the future to increase the volume of the cham-
ber and to individualize the size of the device according to
the severity of the heart failure and the patient size.
Should the device be used for long-term, the vascular
graft could be placed through another intercostal space
Table 1 Hemodynamic data before and after acute heart failure
CO (L/min) PCWP (mmHg) MAP (mmHg) LVEDP (mmHg)
Normal 3.84 ± 0.21 6.50 ± 1.06 93.75 ± 4.06 -1.00 ± 1.69
HF 2.75 ± 0.19* 11.00 ± 1.31* 59.13 ± 5.54* 3.25 ± 1.39*
HF heart failure, CO Cardiac output, PCWP pulmonary capillary wedge pressure,
MAP mean aortic pressure, LVEDP left ventricular end-diastolic presssure Values
are given as mean ± SD
* Normal vs. HF (p <0.001)
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to avoid the major incision problems. In this study, the
fact that in two of the sheep that had the ETPACD
continuously used postoperatively for 1 week, the device
worked well with no complications and no thrombus
formation in the chamber of ETPACD, indicating that
this device has potential to be used for mid-term or
long-term use postoperatively.
Furthermore, for a long-term use, the device could be
easily observed for the function of the helium gas cham-
ber as well as the blood chamber.
Table 2 Hemodynamic variables before and during mechanical support by the IABP or ETPACD in acute heart failure
Device CO (L/min) SAP (mmHg) MADP (mmHg) LVEDP (mmHg) LCAF (ml/min)
HF baseline 2.81 ± 0.22 78.00 ± 5.81 55.63 ± 5.98 3.25 ± 1.39 234.75 ± 20.30
40-ml IABP 3.04 ± 0.20** 72.75 ± 5.80* 62.63 ± 7.37* 2.50 ± 1.31 258.50 ± 20.13**
65-ml OTPACD 3.19 ± 0.19*,*** 66.13 ± 5.92*,**** 70.50 ± 7.50*,**** 2.38 ± 1.19 277.00 ± 19.00*,***
Values are given as mean ± SD. HF vs. IABP, HF vs. ETPACD (* p value < 0.05, **p value < 0.01)
IABP vs.OTPACD (*** p value < 0.05,**** p value < 0.01)
HF heart failure, CO cardiac output, SAP systolic aortic pressure, MADP mean aortic diastolic pressure, LVEDP left ventricular end diastolic presssure, LCAF left
carotid artery flow
Fig. 3 Actual trace of a. Aortic pressure wave with IABP assisting (1:2) and b. Aortic pressure wave with ETPACD assisting (1:2)
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The valveless characteristics of the ETPACD consist-
ing of polyurethane and heparin-coated inner surface
make it highly biocompatible in order to reduce the use
of anticoagulant agents and to decrease free hemoglobin
in plasma, therefore suitable for long-term support of
patients with heart failure. In addition, the implantation
of the device allows mobilization of the patient, limited
only by the driving line and console.
Lastly, the ETPACD was designed to be easily removed
should the heart function be recovered and the use of
ETPACD be terminated. A small thoracotomy is enough
to facilitate the placing of large titanium clips near the
aortic side of the vascular to completely close the graft.
Clinical implications
Although the present study is an experimental investi-
gation, we may draw some outlines for the possible
indications to insert ETPACD. First, the indication for
ETPACD is similar to IABP. When a patient has left
ventricular failure after cardiac surgery with difficulty
Fig. 4 The left carotid artery flow with IABP (1:2) (a) and with ETPACD (1:2) (b)
Fig. 5 a: Photograph of a sheep one week after the implantation of extra-thoracic paraaortic counterpulsation device (ETPACD).The picture shows
that the sheep survived well with the ETPACD (shown by the arrow). terpulsation device (ETPACD). The picture shows that the sheep survived
well with the ETPACD (shown by the arrow). b. The sheep was then sacrificed and the ETPACD was examined for possible thrombus formation.
There was no thrombus formation in the chamber of ETPACD
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to come off cardiopulmonary bypass or need left ven-
tricular support with low cardiac output, insertion of
IABP or ETPACD could be considered. However, if it
is predicted that IABP may not provide enough sup-
port such as in patients with low blood pressure in
whom IABP may not provide high enough blood
pressure for life support or an IABP has been
inserted but not provide effective support, ETPACD
may provide better support. Second, when an IABP
support is used for more than a week or predicted to
be lasting for more than a week, ETPACD may be
considered since it has fewer vascular complications.
Third, when the left ventricular failure is quite severe
that may need left ventricular assistance device,
ETPACD may be tried to insert as the first-line
support. However, the above implications need to be
further studied.
Limitations
The efficacy of the PACD, however, is limited by the
usual restrictions of counterpulsation techniques, includ-
ing the requirement of a minimum aortic systolic pres-
sure and stroke volume generated by the failing heart, a
competent aortic valve to avoid regurgitation of the
counterpulsation volume into the left ventricle thus
creating unfavorable overload, as well as the constraints
imposed by the heart rate, because excessively short
diastolic periods do not allow the formation of an effect-
ive counterpulsation wave. Therefore, in situations of
extreme hemodynamic decompensation, the use of an
left ventricular assisting device or a total artificial heart
is inescapable [17–20]. In addition, the ETPACD requires
thoracotomy for implantation and therefore in cases
of mild hemodynamic decompensation expected to
last for a short period of time, the IABP with the
advantage of percutaneous insertion remains the first
line option.
Conclusion
In conclusion, this study demonstrated that both
ETPACD and IABP provided benefit of circulatory
support in acute heart failure with better effect on
hemodynamic parameters provided by ETPACD. The
advantages of this device, including low cost, ease of
implantation and removal, wide availability of the driving
consoles, and high biocompatibility, may suggest that
ETPACD a desirable alternative for the long-
termmechanical support of heart failure or as a bridge to
transplantation or myocardial recovery. Therefore,
ETPACD with theoretical larger stroke may become a
promising counterpulsation device for treatment of heart
failure.
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